Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1501-1510 Newer>

Managed Care October 2004 Tony Schueth	Formulary Standards Key To E-Prescribing Success Electronic prescribing needs standardization before it's adopted by the masses. Start with the format of formulary databases.
BusinessWeek November 8, 2004 Lorraine Woellert	How Much Is That Brain Scan? If turning Americans into price-conscious health-care shoppers is ever going to work, it will require wholesale changes in many of the industry's most basic business practices.
The Motley Fool October 29, 2004 Bill Mann	King, Knave, or Village Idiot? Troubled King Pharmaceuticals' latest accounting woes threaten to scuttle its merger with Mylan.
The Motley Fool October 29, 2004 Brian Gorman	Elan Bides Its Time Is the Irish pharmaceutical stronger from its near-death experience?
The Motley Fool October 29, 2004 W.D. Crotty	Future Looking Up for Flamel As the nanotech/biotech company earns a profit -- keep an eye on two drugs in phase 3 trials.
The Motley Fool October 29, 2004 Selena Maranjian	Flu Shots for the Elite The flu shot shortage offers some food for thought for investors. Here are some statistics showing the establishment has some problems with the priorities when it comes to the flu.
The Motley Fool October 28, 2004 Bill Mann	Glaxo's Mild Depression The British drug maker sees increased generic competition for its anti-depressant drugs. Total constant currency sales slipped to $7.7 billion in the current quarter from $8.5 billion last year.
The Motley Fool October 28, 2004 Brian Gorman	Cardinal's Good News: No News The drug wholesaler took a major step toward rehabilitating itself with the release of its 10-K.
The Motley Fool October 28, 2004 Rich Duprey	Has Dentsply's Smile Dimmed? Dental supply company reports record earnings, but slipping sales in key markets. The stock was knocked down by about 4%.
The Motley Fool October 27, 2004 Charly Travers	Cubist's Growing Pains The pharmaceutical is going to have to work through some growing pains and make strides toward profitability before the performance of the stock will match the performance of its drug.
<Older 1501-1510 Newer> Return to current articles.